Coherus Oncology (CHRS) Receivables (2013 - 2026)

Coherus Oncology has disclosed Receivables across 13 years of filings, most recently posting $14.3 million for Q2 2026.

• In Q2 2026, Receivables fell 88.09% year-over-year to $14.3 million; the TTM figure through Jun 2026 stood at $14.3 million (down 88.09% YoY), while the FY2025 annual figure was $18.4 million, down 84.94% from the prior year.
• Receivables came in at $14.3 million for Q2 2026 at Coherus Oncology, down from $22.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $313.6 million in Q2 2024 to a low of $14.3 million in Q2 2026.
• Average Receivables over 5 years is $142.2 million, with a median of $118.3 million recorded in 2022.
• Year-over-year, Receivables jumped 180.07% in 2024 and tumbled 88.09% in 2026.
• Over 5 years, Receivables stood at $110.0 million in 2022, then soared by 136.92% to $260.5 million in 2023, then sank by 53.04% to $122.3 million in 2024, then sank by 84.94% to $18.4 million in 2025, then decreased by 22.61% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $14.3 million in Q2 2026, $22.5 million in Q1 2026, and $18.4 million in Q4 2025.